Impact of Biosecure starting to come into focus

The U.S. government’s decision to brand WuXi AppTec a Chinese military company signals that the Trump administration intends to treat life sciences as a national security front. The full scope of the restrictions the listing triggers remains unclear. What is clear is the bipartisan will in Washington to reduce U.S. dependence on China’s biopharma sector.

The immediate impact of the Pentagon’s designation of WuXi AppTec Co. Ltd. (Shanghai:603259; HKEX:2359) is likely to be reputational. Biopharmas and investors may be reluctant to contract with a company the U.S. government has branded a security risk. ...